AbbVie Announces European Fixed Income Investor Meetings

News provided by

Nov 02, 2016, 08:30 ET

NORTH CHICAGO, Ill., Nov. 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has mandated Barclays, BofA Merrill Lynch, Deutsche Bank, J.P. Morgan and Morgan Stanley (Global Coordinator) to organize a series of European fixed income investor meetings, commencing on Wednesday, November 9, 2016. An inaugural EUR-denominated senior unsecured multi-tranche benchmark transaction to refinance indebtedness will follow, subject to market conditions. AbbVie intends to use the proceeds of any offering together with existing cash on hand to repay all or a part of its 1.75% Senior Notes that mature on November 6, 2017. Relevant stabilization regulations including FCA/ICMA will apply.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction.

This announcement is not being made, and this announcement has not been approved, by an authorized person for the purposes of section 21 of the United Kingdom Financial Services and Markets Act 2000, as amended (the "FSMA").‎ Accordingly, this announcement is not being distributed to, and must not be passed on to, the general public in the United Kingdom or to persons in the United Kingdom save in circumstances where section 21(1) of the FSMA does not apply. This announcement is made to and is directed only at persons in the United Kingdom having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) or are high net worth companies, unincorporated associations etc. falling within Article 49(2), in each case of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and to those persons to whom it can otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This announcement and the securities referred to herein are, and will be made, available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, such relevant persons. No other person should rely or act upon it. This announcement is not intended for distribution to and must not be passed on to any retail client.

The company has filed a shelf registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the "SEC"). Any offering of securities will be made only by means of a prospectus supplement, which will be filed with the SEC. In the event that the company proceeds with an offering, you may obtain a copy of the prospectus supplement and accompanying prospectus for the offering by visiting EDGAR on the SEC website at www.sec.gov, or from the company or the underwriters of that offering by contacting Barclays at 1-888-603-5847, BofA Merrill Lynch at 1-800-294-1322, Deutsche Bank at 1-800-503-4611, J.P. Morgan collect at +44-207-134-2468 and Morgan Stanley at 1-866-718-1649.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view our Facebook and LinkedIn pages.

SOURCE AbbVie